secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001628280-24-049570
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics enters $75M at-the-market equity offering with Leerink Partners
--------------------------------------------------------------------------------

- ATM facility allows sale of up to $75M of common stock from time to time.
- Leerink Partners receives 3.0% commission on gross proceeds; company reimburses certain expenses.
- Net proceeds to fund R&D of product candidates and working capital / general corporate purposes.
- Shares offered under effective S-3 filed Nov 2022; prospectus supplement dated Dec 2, 2024.
- Company not obligated to sell any shares; agreement terminates upon full sale or earlier termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828024049570/0001628280-24-049570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828024049570/cntx-20241202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer